Skip to main content

Silexion Therapeutics Corp 8-K, filed Sep 28, 2026

Silexion Therapeutics Corp (SLXN)

8-K 2026-09-28 For: 2026-09-28
View Original
Added on September 28, 2026

About this 8-K

Silexion Therapeutics Corp filed this 8-K on September 28, 2026.

Silexion Therapeutics Corp reported positive preclinical findings that SIL204 uses circulating lipoproteins for cellular uptake and dose-dependent mutant KRAS silencing; lipid depletion reduced knockdown (P < 0.001), while physiological lipid levels enabled uptake without artificial carriers. AI summary

Items reported

  • Item 7.01: Regulation FD disclosure
  • Item 9.01: Financial statements and exhibits